[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mood-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mood-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,44,76,105,147,188,213,239,264,286,315,341,370,413,442,482,507,534,546,573,607,628,656,681,710],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054287","an-innovative-master-platform-for-clinical-trials-in-mood-disorders-100054287",false,"NCT06408012","An Innovative Master Platform for Clinical Trials in Mood Disorders","Enabling Neuroscience Research Approaches for Brain, feeLings and Emotions (ENABLE): An Innovative Platform for Clinical Trials in Mood Disorders","ENABLE","Inclusion Criteria\n\nPatients:\n\n1. 16 years of age or older.\n2. Meet criteria for bipolar or depressive disorders as defined by DSM-5.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.\n\nInclusion Criteria\n\nHealthy Comparison (HC) Participants:\n\n1. 16 years of age or older.\n2. No history of psychiatric disorders (according to DSM-5) or significant unstable medical conditions.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.",true,"ALL","16 Years",{"count":22,"type":23},2200,"ESTIMATED","1 Day","OBSERVATIONAL","Mood disorders such as depression and bipolar disorder affect over 350 million people around the world. While several effective treatments exist, it is often difficult to match the right treatment to an individual person. Repeated efforts to find the right treatment contribute to poor functioning, low quality of life, and prolongs the time it takes to get well. Most areas of medicine are able to use 'biomarkers' or clinical tests, blood tests, or imaging to help diagnose and treat illness. The search for biomarkers in mood disorders is advancing, but one roadblock to progress is the lack of large, standardized studies of mood disorders that are needed to accurately identify biomarkers. The aim of the ENABLE platform is to provide the Canadian neuroscience community a standardized way of collecting biomarker data from individuals with a range of mood disorders symptoms. In addition, this 'master clinical trial platform' framework will provide a pool of participants who can be recruited into biomarker-based clinical trials.",[28,29,30],"Mood Disorders","Depressive Disorder","Bipolar and Related Disorders","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2023-10-17",{"date":39,"type":23},"2029-03-31",{"name":41,"class":42},"St. Joseph's Healthcare Hamilton","OTHER",9,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100604914","phase-ii-engagement-and-clinical-impact-of-the-teleo-virtual-therapy-platform-in-clinical-settings-100604914","NCT07155707","Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings","Inclusion Criteria:\n\n* Diagnosed with a mood and\u002For anxiety disorder\n* Have proficiency to participate in psychotherapy in English\n* Scheduled to begin therapy at one of the study sites\n* RCADS score \\> 65\n\nExclusion Criteria:\n\n\\- Comorbid diagnosis of intellectual disability, autism spectrum disorder, psychotic disorders, high-risk suicidal behaviors requiring immediate hospitalization, substance use disorders, or other physical or mental condition that would prohibit them from engaging in telehealth settings.","5 Years","14 Years",{"count":53,"type":23},156,"INTERVENTIONAL",[56],"NA","This Phase II trial will examine engagement in telehealth for children undergoing psychotherapy. Specifically, the trial will examine patient engagement in Teleo, a virtual therapy platform specifically designed for psychotherapy with youth, as compared to standard video conferencing.",[59,28],"Anxiety",[61,62,59,63,64,65],"Teletherapy","Therapeutic Engagement","Depression","Youth Mental Health","Digital Mental Health","2026-06-26",{"date":68,"type":35},"2026-06-29",{"date":70,"type":35},"2026-06-24",{"date":72,"type":23},"2027-09-15",{"name":74,"class":42},"Stanford University",2,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":18,"sex":19,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":4,"leadSponsor":101,"locationsCount":104},"100059955","evaluation-of-patients-with-mood-and-anxiety-disorders-and-healthy-volunteers-100059955","NCT00024635","Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","The Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","* INCLUSION CRITERIA:\n* Subjects ages 3 to 99 may enroll in the protocol.\n* Subjects must be competent to comprehend the purpose of the screening process and to provide written informed consent and be willing to participate in NIMH IRB approved research protocols. Minors will be asked to assent and their parents will sign the consent form.\n\nEXCLUSION CRITERIA:\n\n-Current alcohol or substance use or dependence (excluding nicotine) within the past 3 months of sufficient magnitude to require independent, concurrent treatment intervention (e.g. Antabuse or opiate treatment, but not including self-help groups).","3 Years","99 Years",{"count":86,"type":23},16000,"The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols in the Experimental Therapeutics and Pathophysiology Lab (ETPB) at the National Institute of Mental Health (NIMH) and for the collection of natural history data. In addition the protocol will allow clinicians to gain more experience in the use of a variety of polysomnographic and high-density EEG recordings. Subjects in this protocol will undergo an evaluation which may include: a psychiatric interview; a diagnostic interview; rating scales; a medical history; a physical exam; brain magnetic resonance imaging (MRI); electroencephalography (EEG); electrocardiography (EKG), magnetoencephalography (MEG); blood, saliva and urine laboratory evaluation; and a request for medical records. Subjects may also be asked to complete questionnaires about attitudes towards research and motivation for research participation. The data collected may also be linked with data from other mood and anxiety disorder protocols (e.g., brain imaging, DNA, psychophysiology tests, treatment studies, etc) for the purposes of better understanding the diagnosis, pathophysiology, and treatment response of patients with mood disorders. Parents of minors will be interviewed. Upon conclusion of the screening process, subjects will either be offered participation in a research protocol and will sign the appropriate informed consent, or will be considered not appropriate for participation in research and will be referred back into the community. The current protocol thus serves as an entry point for individuals with mood or anxiety disorders or healthy volunteers to enter NIMH IRB approved ETPB protocols.",[28,89,90,91,63],"Anxiety Disorders","Healthy Volunteers","Bipolar Disorder",[93,59,94,95,96],"Screening","Mood","Diagnostic Testing","Natural History",{"date":98,"type":35},"2026-06-25",{"date":100,"type":35},"2001-02-02",{"name":102,"class":103},"National Institute of Mental Health (NIMH)","NIH",1,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":18,"sex":19,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":54,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":104},"100527171","whole-body-hyperthermia-for-mood-and-anxiety-disorders-100527171","NCT06144294","Whole-Body Hyperthermia for Mood and Anxiety Disorders","Inclusion Criteria\n\n* Group 2\n\n  * Arm 1: Healthy women or transgender men 18-50 years of age, ≤ 6 months postpartum\n  * Arm 2: Women and transgender men 18-50 years of age, ≤ 6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI.\n  * Arm 3: Healthy adults of both sexes 18-50 years of age.\n  * Arm 4: Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the Mini International Neuropsychiatric Interview (MINI)\n* Group 2: Sub-study\n\n  * Subjects enrolled in Group 2 are eligible for an optional additional sub-study (Group 2: Sub-study); inclusion criteria are the same as for Group 2.\n\nExclusion criteria for all:\n\n* For logistics, we will exclude individuals with BMI \\>30 and waist size \\> 35, who may not fit comfortably in the sauna dome for all cohorts described above.\n* For contraindications to hyperthermia, we will exclude from all cohorts listed above, individuals with severe cardiovascular disease, including congestive heart failure, coronary artery disease, uncontrolled hypertension, and hypotension; pregnancy; active substance use disorders; recent major injuries or surgeries (\\\u003C1 week prior); impaired sweating (those with multiple sclerosis, diabetes mellitus with neuropathy, central nervous system disease, heat insensitivity); a history or family history of malignant hyperthermia, fever or active signs of infection; taking medications that may have interactions with hyperthermia (for example, barbiturates, diuretics, and beta blockers) and the use of an antipyretic or anihistamine medication in the 12 hours prior to the WBH intervention. Individuals with above mentioned conditions will be excluded since either WBH might deteriorate their conditions or it is unknown how their condition will be affected by WBH.\n* For contraindications to immune analyses, we will exclude individuals with conditions that might affect immune analyses, including individuals with known active autoimmune or endocrine disease and individuals with active infection at baseline.\n\nAdditional exclusion criteria by cohort or applicable study group:\n\n* Group 2\n\n  * Arm 1: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 2: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n  * Arm 3: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 4: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n* Group 2 and Group 2: Sub-study - All participants\n\n  * For contraindications to use of the e-Celsius capsule that will be used to measure core temperature, we will exclude individuals with pacemakers or any other electric medical implant, individuals with a current intestinal disorder that could lead to obstruction of the digestive tract including gastroparesis, individuals with history of diverticula, individuals with history of past surgical procedures in the gastrointestinal tract, individuals with a swallowing disorder and individuals with Crohn's disease.\n* Study Group 3 - All participants\n\n  * For contraindications to MRI, individuals with metal in the body will be excluded from participating in the MRI portion of the research since magnetic fields in MRI scanners can cause dangerous interactions in patients with metallic foreign bodies: projectile effect, twisting, burning, artifacts, and device malfunction (interference with a pacemaker).","18 Years","50 Years",{"count":114,"type":23},240,[56],"This study aims to examine the scientific mechanisms of whole-body hyperthermia (WBH), a novel, rapidly acting, single session antidepressant and anxiolytic therapy. It also aims to determine its feasibility and acceptability in women with postpartum depression (PPD). The study will enroll four cohorts of participants: healthy postpartum controls; postpartum women with PPD; healthy adult controls; and adults with major depressive disorder or anxiety disorders in a longitudinal protocol.",[118,28,89,119],"Postpartum Depression","Postpartum Anxiety",[121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136],"postpartum depression","mood disorders","anxiety disorders","postpartum anxiety","whole-body hyperthermia","antidepressant therapy","anxiolytic therapy","postpartum feasibility and acceptability","psychoneuroimmunology","Broad-band neural suppression","EEG","Likert scale","inflammatory activity","pro-inflammatory cytokines","precision functional brain maps","fMRI","NOT_YET_RECRUITING","2026-06-18",{"date":140,"type":35},"2026-06-23",{"date":142,"type":23},"2028-06",{"date":144,"type":23},"2032-12",{"name":146,"class":42},"Weill Medical College of Cornell University",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":54,"phases":157,"briefSummary":159,"conditions":160,"keywords":171,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":104},"100555424","phase-2-investigation-of-the-antidepressant-effects-of-2r6r-hnk-an-enhancer-of-synaptic-glutamate-release-in-treatment-resistant-depression-100555424","NCT06511908","Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Ability of participant to understand and willingness to sign a written informed consent document. To verify this, participants must score \\>= 80% on the consent quiz.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. 18 to 70 years of age.\n4. All participants must have undergone a screening assessment under protocol 01-M-0254.\n5. Participants must fulfill DSM-IV or DSM-5 criteria for MDD, single episode or recurrent without psychotic features, based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P). Participants must be experiencing a current major depressive episode lasting at least two weeks.\n6. Participants must have an initial score of \\>= 20 on the MADRS and a YMRS score of \\\u003C12 within one week of study entry and upon entry into Phase II.\n7. Ability to take intravenous medication and be willing to adhere to the (2R,6R)-HNK regimen.\n8. Participants must have a current or past history of lack of response to at least one adequate antidepressant trial (may be from the same chemical class), with at least one in the current major depressive episode, operationally defined using the modified Antidepressant Treatment History Form (ATHF); non-response to an adequate trial of ECT or TMS would count as an adequate antidepressant trial.\n9. For individuals of reproductive potential: use of highly effective contraception starting at the time of enrollment and agreement to use such a method during study participation and for an additional four weeks after the end of Study Phase II.\n10. For males of reproductive potential: use of condoms or other methods from the time of enrollment to ensure effective contraception with partner, and for an additional 90 days after the end of Phase II.\n11. Agreement to adhere to Lifestyle Considerations throughout study duration.\n12. Medically healthy, or with stable, treated, chronic medical conditions (provided any medications are not excluded)\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current use of disallowed concomitant medications or transcranial magnetic stimulation (TMS) two weeks prior to the start of Phase II.\n2. Treatment with a reversible monoamine oxidase inhibitor (MAOI) four weeks prior to the start of Phase II.\n3. Treatment with fluoxetine, aripiprazole, or brexpiprazole five weeks prior to the start of Phase II.\n4. Treatment with clozapine or electroconvulsive therapy (ECT) four weeks prior to the start of Phase II.\n5. Ongoing treatment with moderate or strong CYP3A4\u002F5 inhibitors or inducers\n6. Lifetime history of deep brain stimulation.\n7. Previous antidepressant non-response to ketamine or esketamine (full course).\n8. No structured psychotherapy will be permitted during the total duration of the study. Participants unable or unwilling to stop psychotherapy will be unable to participate in the study.\n9. Pregnancy or lactation.\n10. Current psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-IV or DSM-5.\n11. Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to screen and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to starting Phase II. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician. Due to the interactions between cannabis and SSRIs, frequent cannabis use during previous antidepressant treatment will result in that treatment being considered a failed trial for eligibility purposes.\n12. Participants with a DSM-IV or DSM-5 Axis II diagnosis of borderline or antisocial personality disorder.\n13. Participants with a history of head injury that resulted in loss of consciousness exceeding five minutes (for the imaging component of the study).\n14. No serious, unstable medical illnesses including but not limited to the following body systems and organs or those that in the judgment of the Principal Investigator pose a risk to the participant's ability to safely participate in the study: Hepatic diseases (e.g. active viral hepatitis infection or cirrhosis of the liver, any liver disease with Child-Pugh score \\>=5), cardiovascular disease (including ischemic heart disease, coronary artery disease, congestive heart failure, poorly controlled hypertension due to risk of further blood pressure elevation and increase in demand on cardiac function from study drug), renal\u002Furologic (e.g chronic kidney disease or acute kidney injury, history of bladder dysfunction due to theoretical risk of ketamine-induced cystitis, moderate to severe renal impairment of any etiology), endocrinologic (including uncontrolled diabetes due to association with progressive abnormality of the microvasculature and nervous system), or neurologic disease (e.g. elevated intraocular pressure or history of or presence of diseases that are associated with elevated intracranial pressure).\n15. Participants with unstable clinical hyperthyroidism or hypothyroidism.\n16. Participants with one or more seizures without a clear and resolved etiology.\n17. Clinically significant abnormal laboratory tests specifically defined by:\n\n    * Alkaline phosphatase (Alk Phos) \\> 150 U\u002FL\n    * Alanine aminotransferase (ALT) \\> 55 U\u002FL\n    * Aspartate aminotransferase (AST) \\> 34 U\u002FL\n    * Total bilirubin (TB) \\> 1.2 mg\u002FdL\n    * Direct bilirubin (DB) \\> 0.5 mg\u002FdL\n    * 25-hydroxyvitamin D \\\u003C 20 ng\u002FmL\n    * Folate \\\u003C 2ng\u002FmL\n    * Vitamin B12 \\\u003C 200 pg\u002FmL\n18. Moderate to severe renal impairment with body surface area corrected eGFR \\\u003C60mL\u002Fmin.\n19. Participants who, in the Principal Investigator's judgment, pose a current serious suicidal or homicidal risk.\n20. Positive HIV test.\n21. Contraindications to MRS (metal in body, claustrophobia, etc. for imaging)\n22. Participants with COVID-19 or suspected COVID-19\n23. Inability to read and understand English. Non- English speakers will not be eligible as most of the required monitoring and rating instruments are not validated in languages other than English.","70 Years",{"count":156,"type":23},50,[158],"PHASE2","Background:\n\nMajor depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective. Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can better treat the symptoms of MDD.\n\nObjective:\n\nTo test a study drug (HNK) in people with MDD.\n\nEligibility:\n\nPeople aged 18 to 70 years with MDD. They must have had a screening assessment under protocol 01-M-0254.\n\nDesign:\n\nParticipants will be tapered off their current MDD drugs over 2 to 5 weeks. They will stay off of the drugs for up to 2 weeks prior to starting the study medication and procedures. They will have a physical exam with blood tests. They will have tests of their heart function, mood, and thinking. They will answer questions about their symptoms. They may choose to have imaging scans and scans of their brain activity.\n\nHNK is given through a tube attached to a needle inserted into a vein. Participants will receive infusions on this schedule:\n\nThey will receive 4 infusions over 2 weeks. They will stay in the clinical center overnight after each infusion or for the duration of the study.\n\nThey will receive no drugs for 2 to 3 weeks.\n\nThey will have 4 more infusions over 2 weeks, with overnight stays after each or for the duration of the study.\n\nOne set of 4 infusions will be the HNK. The other set of 4 infusions will be a placebo. A placebo looks just like the real drug but contains no medicine. Participants will not know when they are getting the HNK or placebo.\n\n...",[161,162,163,164,165,166,167,168,29,63,169,28,170],"Suicide","Depressive Disorder, Treatment-Resistant","Ketamine","Molecular Mechanisms of Pharmacological Action","Neurotransmitter Agents","Excitatory Amino Acid Agents","Physiological Effects of Drugs","Depressive Disorder, Major","Mental Disorders","Behavioral Symptoms",[172,163,173,174,175,176,177,178,179],"Major Depressive Disorder","Biomarkers","Neuropharmacology","Magnetic Resonance Imaging","Magnetoencephalography","Neurobiology","Glutamate","Hydroxynorketamine","2026-06-13",{"date":182,"type":35},"2026-06-16",{"date":184,"type":35},"2024-11-06",{"date":186,"type":23},"2027-07-01",{"name":102,"class":103},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":18,"sex":19,"minAge":111,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":4,"leadSponsor":212,"locationsCount":104},"100087463","development-of-magnetic-resonance-imaging-techniques-for-studying-mood-and-anxiety-disorders-100087463","NCT00397111","Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders","Development of Functional and Structural Magnetic Resonance Imaging Techniques for the Study of Mood and Anxiety Disorders","* INCLUSION CRITERIA:\n\nHealthy Controls\n\n* Male and female subjects between 18 and 65 years of age\n* Subjects must be able to give written informed consent prior to participation in this study.\n* Subjects who do not currently meet and have never met criteria for any major psychiatric disorder, and who have no known first degree relatives with mood disorders.\n* For cognitive experiments utilizing language stimuli only native English speakers will be enrolled.\n\nMajor Depressive Disorder\n\n* Male and female subjects between 18 and 65 years of age.\n* Subjects have been found eligible for other ETPB research protocols according to 01-M-0254.\n* Subjects must fulfill DSM-IV or V criteria for Major Depression based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P).\n* Subjects must be able to give written informed consent prior to participation in this study.\n* For cognitive experiments utilizing language stimuli, only native English speakers will be enrolled.\n\nEXCLUSION CRITERIA:\n\nHealthy Control\n\n* Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology, or taking any medication that is likely to influence the imaging parameters-of-interest within 3 weeks of scanning.\n* Women who are pregnant are excluded from the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.\n* Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.\n* A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).\n\nMajor Depressive Disorder\n\n* Presence of Axis 1 psychiatric diagnosis other than Major Depression or an Axis 2 disorder\n* Subjects with major medical or neurological disorders expected to influence cognitive function or are taking any drugs likely to affect mood or cognitive function within 1 week of study participation. Depressed subjects will not be tapered\u002Fwithdrawn from medications under this study.\n* A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).\n* Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology.\n* Women who are pregnant or breastfeeding will be excluded from MRI portions of the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.\n* Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.","65 Years",{"count":197,"type":23},390,"This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks. Healthy volunteers and individuals with major depressive disorder may be eligible for this study.\n\nParticipants undergo magnetic resonance imaging (MRI) and neuropsychological testing. : Individuals will be asked to participate in an MRI study on one of several scanners. The scanner used will measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. The scan may involve They watching a screen presenting images or doing a task in which they respond to pictures or sounds. Participants may be asked to return for additional scans.\n\nThe study also involves neuropsychological tests, which assess cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer.",[28,89],[201,202,136,203,204,96,205,206],"Morphometry","BOLD","Spectrometry","Relaxometry","Healthy Volunteer","HV","2026-06-05",{"date":209,"type":35},"2026-06-08",{"date":211,"type":35},"2006-12-06",{"name":102,"class":103},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":54,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100489874","rxwell-to-decrease-post-operative-opioid-use-in-total-knee-or-hip-arthroplasty-100489874","NCT05658796","RXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty","Telemedicine-delivered Digital Cognitive Behavioral Intervention to Decrease Post-operative Opioid Use Among Patients Undergoing Total Knee or Hip Arthroplasty","RxWell","Inclusion Criteria for the RXWell Study:\n\n* Adults \\>18 years\n* Scheduled for elective primary total knee arthroplasty (TKA) or hip replacement (THA) at the approved UPMC hospitals\n* Moderately high levels of mood disorder symptoms on validated PROMIS measures, defined as a T-score \\> or = to 60 on PROMIS Anxiety 4a short form and\u002For PROMIS Depression4a short form\n\nExclusion Criteria for the RXWell Study:\n\n* Patients undergoing non-elective surgery or secondary arthroplasty\n* Active delirium, neurocognitive impairment, or severe intellectual disability\n* No access to a smart device (phone or tablet)\n* Active alcoholism (defined as daily use of more than 1 liter of wine and \u002For 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)\n* Profound mood disorders requiring immediate intervention such as suicidal ideation, defined as a PROMIS Depression score of more than 70\n* A PROMIS Anxiety and\u002For Depression T-score \\>70, which corresponds to severe anxiety and depression.\n\n  * Patients needing immediate care will be referred to psychiatrists and primary team.","100 Years",{"count":223,"type":23},150,[56],"It is envisioned that multipronged benefits from this pilot work for the UPMC ISD and its members. It is expected the RxWell platform to provide the following benefits: expansion of the use of RxWell to all UPMC ISD members providing peri-operative mood management with advantage of improved peri-operative outcomes, improving saving for the UPMC ISD by hastening the recovery and decreased resource utilization, and addition to the high-value care of UPMC with this holistic approach to patient perioperative care",[28,59,227,63,89,228],"Depressive Symptoms","Anxiety Depression","2026-06-01",{"date":231,"type":35},"2026-06-03",{"date":233,"type":35},"2023-01-27",{"date":235,"type":23},"2026-12-30",{"name":237,"class":42},"University of Pittsburgh",3,{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":154,"enrollmentInfo":247,"targetDuration":4,"studyType":54,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":43},"100489695","clinical-study-evaluating-pharmacogenomics-informed-pharmacotherapy-versus-dosing-as-usual-in-psychiatric-disorders-100489695","NCT05656469","Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders","A New Intervention for Implementation of Pharmacogenetics in Psychiatry","PSY-PGx","Inclusion Criteria:\n\n1. Suffer from a depressive episode (major depressive disorder and bipolar disorder (currently depressive episode)) (as assessed by the MINI International Neuropsychiatric Interview (M.I.N.I.) in agreement with Diagnostic and Statistical Manual (DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D) with a score of 14 or higher) and\u002For suffer from an anxiety disorder (panic disorder, generalised anxiety disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH- A) with a score of 18 or higher) and\u002For suffer from a psychotic disorder (schizophrenia and schizoaffective disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Positive and Negative Symptom Scale (PANSS) with a score of 75 or higher).\n2. Have had an inadequate response to at least 1 psychotropic treatment during their life-time. Inadequate response is defined as insufficient efficacy of a psychotropic treatment when dosed high enough and maintained long enough, or discontinuation of a psychotropic treatment due to AEs or intolerability.\n3. Are about to switch (or have switched within the last 2 weeks prior to first contact with an investigator) to sertraline or escitalopram (for patients with mood or anxiety disorders), or to aripiprazole or risperidone (for patients with psychotic disorders) due to an inadequate response to or intolerance of the current\u002F previous medication.\n4. Currently receiving inpatient or outpatient psychiatric treatment.\n5. Be able to understand the requirements of the study and provide written informed consent to participate in this study; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.\n6. To give written consent to the use and disclosure of clinical data from their medical records for the purpose of this study.\n7. Age between ≥16 and \\\u003C70 years.\n8. Ownership of a mobile phone (Android or iOS operation system) for passive monitoring.\n\nExclusion Criteria:\n\n1. Patients with a history of prior pharmacogenomic testing\n2. Patients with no prior use of psychotropic medication (medication-naïve patients)\n3. Severe somatic comorbidities as reported in the subject's medical history or based on clinical chemistry\u002Felectrocardiography (ECG) results up to six months ago. If any of these comorbidities is detected on the basis of physical examination and\u002For clinical chemistry and\u002For ECG at the screening visit, participation is not possible.\n\n   * Liver disease defined as follows: Alanine-Aminotransferase (ALAT) \\>70u\u002FL\n   * Renal disease: Estimated glomerular filtration rate (eGFR) \\\u003C 60ml\u002Fmin\u002F1.73m2\n   * Diabetes: Blood glucose \\> 11.1 mmol\u002FL or twice a fasting glucose \\> 7.0 mmol\u002FL\n   * Cardiac disease: prolonged QT-interval.\n4. Alcohol and\u002For substance abuse and\u002For dependence (except nicotine)\n5. Polypharmacy defined as the routine use of five or more medications including over- the-counter, prescription and\u002For traditional and complementary medicines used by a patient (WHO 2019).\n6. Inability to use the mobile phone application\n7. Pregnant or breastfeeding women",{"count":248,"type":23},2500,[56],"A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.",[28,89,252],"Psychotic Disorders",[254],"Pharmacogenetics","2026-05-29",{"date":257,"type":35},"2026-06-02",{"date":259,"type":35},"2023-02-23",{"date":261,"type":23},"2026-09",{"name":263,"class":42},"Parnassia Groep",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":54,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":104},"100587519","a-preventive-behavioral-intervention-for-young-adults-with-psychotic-experiences-100587519","NCT06929442","A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences","A Randomized Controlled Trial of a Preventive Behavioral Intervention for Young Adults With Psychotic Experiences","Inclusion criteria:\n\n1. 18-30 years old\n2. Enrolled as a first or second year student (i.e., freshman or sophomore) in an undergraduate program at the college or university where the intervention takes place\n3. Students who endorse some psychotic experiences (Peter's et al. Delusion Inventory (PDI) score \\> 3)\n\nExclusion criteria:\n\n1. Inability to provide informed consent\n2. Not proficient in English\n3. Current self-reported Diagnostic Statistical Manual 5 (DSM-5) diagnosis with active symptoms (such as active psychotic symptoms, current suicidality, serious active alcohol or substance use, marked deterioration in functioning over the prior month) determined by clinical interview with participant, or self-report of a psychiatric diagnosis that necessitates close monitoring or individual therapy and\u002For inpatient or partial hospitalization\n4. Current enrollment in psychological or behavioral health treatment.\n5. Current use of psychotropic medications (other than stimulants) prescribed by a physician.\n6. A diagnosis of a serious, chronic mental illness as determined by the Mini-International Neuropsychiatric Interview (MINI)","30 Years",{"count":273,"type":23},192,[56],"This is a randomized controlled trial testing the efficacy of Resilience Training in college students with elevated transdiagnostic risk for developing a serious mental illness.",[252,28,89],"2026-05-07",{"date":279,"type":35},"2026-05-11",{"date":281,"type":35},"2025-02-10",{"date":283,"type":23},"2029-06",{"name":285,"class":42},"Massachusetts General Hospital",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":54,"phases":295,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":104},"100599780","feasibility-and-acceptability-of-an-e-learning-dialectical-behavior-therapy-skills-course-100599780","NCT07088939","Feasibility and Acceptability of an E-learning Dialectical Behavior Therapy Skills Course","Feasibility and Acceptability of a Self-guided Internet-delivered Dialectical Behavior Therapy Intervention for Adults With Mental Health Challenges","Inclusion Criteria:\n\n* Ages 18 years old and up.\n* Reside in Ontario.\n* Fluent in English.\n* Able to provide autonomous informed consent\n* Reports at least mild depression and\u002For anxiety symptoms\n* Not currently receiving any psychotherapy or psychosocial interventions.\n* Have access to the internet\n\nExclusion Criteria:\n\n* Practical (e.g., scheduling), acute psychiatric (e.g., suicidal ideation nearly every day, recent hospitalization for mental health reasons), or medical reasons (e.g., upcoming surgery, medical procedure, head injury).\n* Not meeting one or more of the above inclusion criteria",{"count":294,"type":23},40,[56],"Dialectical behavior therapy (DBT) is a comprehensive, third-wave psychological intervention designed for patients with complex and severe behavioral, emotional, and interpersonal dysfunction. DBT has since been adapted to shorter, briefer, \"skills training\" formats, which have been effective for a number of mild-to-moderate mental health conditions, including depression and anxiety. Moreover, internet-delivered formats of DBT (iDBT) have similarly started to build support for their effectiveness, although there are fewer studies on digital formats. One study found that over 12 weeks, iDBT was deemed acceptable (e.g., 50% of participants were still active after 4 weeks) and there were improvements in multiple symptom domains, such as depression, anxiety, suicidality, functional disability, as well as alcohol and substance dependence.\n\nIn the current study, the investigators will examine the feasibility, acceptability, and potential efficacy of a new iDBT intervention, packaged as an online e-learning skills course, with adult participants. The study is a pilot trial as iDBT has never been tested in this format through formal research. Thus, this pilot study aims to examine whether this course is usable, practical, and potentially useful to others in the future. The investigators will recruit up to 40 individuals with mild-to-moderate depression and anxiety for an 8-week study. Following a phone screen to determine eligibility, participants will complete a baseline session where they will provide consent, complete a brief interview and questionnaires, and register for the e-learning skills course. Over the course of 8 weeks, participants will be exposed to material adapted from a DBT manual in a self-guided manner. Participants will complete follow-up assessments at 4 and 8 weeks.",[298,59,63,299,28],"Depression - Major Depressive Disorder","Stress",[301,302,303,304,305],"dialectical behavior therapy","internet interventions","co-developed interventions","feasibility study","digital health","2026-04-30",{"date":308,"type":35},"2026-05-06",{"date":310,"type":35},"2025-07-20",{"date":312,"type":23},"2026-08-01",{"name":314,"class":42},"University of Windsor",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":322,"enrollmentInfo":323,"targetDuration":325,"studyType":25,"phases":4,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":104},"100633192","investigation-on-suicide-risk-factors-of-patients-with-mood-disorders-100633192","NCT07523490","Investigation on Suicide Risk Factors of Patients With Mood Disorders","Investigation on Suicide Risk Factors of Patients With Mood Disorders in China","Inclusion Criteria:\n\n1. Age: 16 to 60 years old;\n2. seeing a doctor in a psychiatric clinic or a general hospital;\n3. Willing to cooperate in this research project;\n4. Sign the informed consent form (minors also need to obtain the informed consent signature of the guardian);\n5. Meet the diagnostic criteria of ICD-11 mood disorder.\n\nExclusion Criteria:\n\n1. unable to understand the contents of the questionnaire;\n2. Serious organic diseases such as cardiovascular disease, brain disease, liver disease and kidney disease, and weak body, which affect the respondents of the questionnaire;\n3. Other circumstances that make it impossible or unwilling to cooperate with the completion of the questionnaire.","60 Years",{"count":324,"type":23},300,"3 Months","This study investigates the level and distribution of suicide risk and learned suicide ability of patients with mood disorders, investigates the related risk factors of suicide and suicide ability formation of patients with mood disorders from multiple dimensions (biological, psychological, social and clinical perspectives) and clarifies their importance, forms a list of suicide risk factors, and establishes a prediction model of learned suicide ability formation. Upon enrollment, participants will undergo comprehensive assessments including blood and urine sample collection and scale evaluation. The collection of scientific blood and urine is mainly used for the exploration of molecular mechanism of disease occurrence and development, the discovery and verification of biomarkers. Scale evaluation includes: Beck Scale for Suicide Ideation , Columbia Suicide Severity Rating Scale,, Hamilton Depression Rating Scale , Hamilton Anxiety Rating Scale, PHQ-9, GAD-7, Personal and Social Function Scale , Schihan Disability Scale , Emotional Adjustment Difficulty Scale , Acquired Capability for Suicide Scale, Interpersonal Needs Questionnaire , Ottawa Self-Injury Scale, Chinese version of Stress Perception Scale and Beck Hopelessness Scale . Follow-up was carried out for 3 months, including whether suicide\u002Fself-injury occurred, current status, and some baseline questionnaires (such as BSI-CV, GAD-7, PHQ-9, HAMD-17,HAMA, etc.).",[28,161],[28,329,330,331],"suicide","Biological Mechanism","prediction model","2026-04-18",{"date":334,"type":35},"2026-04-22",{"date":336,"type":35},"2025-12-31",{"date":338,"type":23},"2027-09-30",{"name":340,"class":42},"Tianjin Anding Hospital",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":18,"sex":348,"minAge":349,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":54,"phases":352,"briefSummary":353,"conditions":354,"keywords":360,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":75},"100480983","cognitive-behavioral-therapy-and-exercise-training-in-adolescents-at-risk-for-type-2-diabetes-100480983","NCT05543083","Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes","CBTeX","Inclusion Criteria:\n\n* Female\n* Age 12-17 years\n* Body Mass Index (BMI)\\>= 85 for age and sex\n* Type 2 Diabetes (T2D) first-or second-degree relative\n* Center for Epidemiologic Studies Depression Scale (CES-D) total score \\>=21\n\nExclusion Criteria:\n\n* T2D\u002F Type 1 Diabetes (T1D) or any major medical condition (e.g. cardiovascular, renal) that would prohibit the ability to participate in exercise training\n* Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) conduct disorder, substance abuse\u002F dependence, obsessive compulsive disorder, panic attacks, post-traumatic stress disorder, anorexia\u002Fbulimia, \\& schizophrenia\n* Insulin sensitizers, weight loss medications \\& chronic steroids\n* Structured weight loss treatment or bariatric surgery\n* Pregnancy, nursing","FEMALE","12 Years","17 Years",{"count":324,"type":23},[56],"The investigators are doing this study to learn more about how to prevent type 2 diabetes in teenage girls. The purpose of this study is to find out if taking part in a cognitive-behavioral therapy group, exercise training group, or a combination of cognitive-behavioral therapy and exercise training groups, decreases stress, improves mood, increases physical activity and physical fitness, and decreases insulin resistance among teenagers at risk for diabetes.",[355,63,29,28,356,357,358,359],"Insulin Resistance","Mental Disorder in Adolescence","Hyperinsulinism","Glucose Metabolism Disorders","Metabolic Disease",[361,362],"Adolescent Type 2 Diabetes Prevention","Exercise Training","2026-04-17",{"date":334,"type":35},{"date":366,"type":35},"2023-06-02",{"date":39,"type":23},{"name":369,"class":42},"Colorado State University",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":54,"phases":379,"briefSummary":380,"conditions":381,"keywords":395,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":104},"100493968","neurostimulation-versus-therapy-for-problems-with-emotions-100493968","NCT05712057","Neurostimulation Versus Therapy for Problems With Emotions","Neurostimulation Enhanced Cognitive Restructuring for Transdiagnostic Emotional Dysregulation: A Component Analysis","Inclusion Criteria:\n\n* age 18 to 55\n* elevated overall score on Difficulties with Emotion Regulation Scale (DERS total score \\>=90)\n* has been in the same type of psychotherapy (including none) for the last 4 weeks\u002F1mo (\\*except for current CBT) and is willing to stay on the same regimen throughout the study.\n* low self-reported use of cognitive restructuring (ERQ restructuring subscale average score \\\u003C 4.7)\n* meets criteria for at least one mood (including Bipolar II w\u002Fo current hypomania), anxiety, stressor, OCD, Impulse Control, ADHD, or eating DSM-5 disorder (except exclusionary diagnoses such as severe anorexia). Note: Both current or partial remission of the disorder will be ok for inclusion into the study.\n* verbal agreement to maintain dose of prescribed psychotropic medication (if any) constant throughout the study, provided they are stable on it for the past 4 weeks (except exclusion medication and except if there is a medical emergency requiring changes in medication).\n* Naïve to rTMS\n\nExclusion Criteria:\n\n* current hypomania (Note: Bipolar II w\u002Fo current hypomanic episode is ok for inclusion)\n* meets diagnostic criteria for current or history of psychotic disorder, or psychotic features,\n* meets diagnostic criteria for Bipolar I disorder\n* meets diagnostic criteria on SCID5 for current alcohol or substance use disorder (moderate and high severity) or meets past history of severe alcohol use disorder\n* unable to read, blind, or deaf, or unwilling to give consent\n* non-English speaker,\n* verbal IQ \\\u003C 90 on the North American Adult Reading Test (NART).\n* current uncontrolled anorexia or other condition requiring hospitalization\n* high risk for suicide defined as either having attempted suicide in past 6 months or reporting current suicidal ideation that includes a method, plan, or intent to die\n* current serious medical illness, including current severe migraine headaches\n* started\u002Fchanged psychotropic medications in the prior 4 weeks, or plans to change medication during the study\n* history of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesions that are contraindications for TMS, devices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator), have left elbow\u002Fhand\u002Fwrist tendonitis\n* conditions associated with increased intracranial pressure, space occupying brain lesion (considered significant and unsafe for TMS by the study MD), transient ischemic attack, cerebral aneurysm, dementia, Parkinson's or Huntington's disease, multiple sclerosis\n* Wellbutrin \\>300mg per day or on daily stimulant\u002FADHD medications above the recommended FDA daily recommendations\n* use of investigational drug or devices within 4 weeks of screening\n* cochlear implants\n* Pregnancy\n* metal in body that would exclude them from the MRI scan; severe claustrophobia\n* is a prisoner or in police custody at time of screening, or has pending court case jeopardizing the participation in the study\n* has had TMS in their lifetime\n* has had CBT in the past 4 weeks or plans to start therapy during the study\n* weighs over 300 pounds (could not fit in MRI scanner)","55 Years",{"count":114,"type":23},[56],"The primary goal of this clinical trial is to evaluate the unique neural and behavioral effects of a one-session training combining emotion regulation skills training, with excitatory repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC). The secondary aim is to identify key changes in the emotion regulation neural network following the combined intervention versus each of the components alone. The third aim is to explore personalized biomarkers for response to emotion regulation training.\n\nParticipants will undergo brain imaging while engaging in an emotional regulation task. Participants will be randomly assigned to learn one of two emotion regulation skills. Participants will be reminded of recent stressors and will undergo different types of neurostimulation, targeted using fMRI (functional MRI) results. Participants who may practice their emotion regulation skills during neurostimulation in a one-time session. Following this training, participants will undergo another fMRI and an exit interview to assess for immediate neural and behavioral changes. Measures of emotion regulation will be assessed at a one week and a one month follow up visit.",[382,28,383,89,384,385,386,387,388,389,390,391,392,393,394],"Emotion Regulation","Stress Disorder","OCD","Impulse Control Disorder","Eating Disorders","Emotional Dysfunction","Emotional Instability","Emotional Distress","Emotional Maladjustment","Emotional Impulsivity","Obsessive-Compulsive Disorder","Emotion Dysregulation","Borderline Personality Disorder",[393,396,397,398,399,400,401,402,403],"Distress Intolerance","Neuromodulation","Neurostimulation","TMS","cognitive restructuring","regulation skills","neuroimaging","Emotion regulation","2026-03-02",{"date":406,"type":35},"2026-03-04",{"date":408,"type":35},"2023-05-15",{"date":410,"type":23},"2027-12-01",{"name":412,"class":42},"Duke University",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":18,"sex":19,"minAge":111,"maxAge":195,"enrollmentInfo":420,"targetDuration":422,"studyType":25,"phases":4,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":4},"100625848","psychobiological-markers-to-improve-diagnosis-and-to-predict-affective-episodes-in-bipolar-disorder-100625848","NCT07427966","Psychobiological Markers to Improve Diagnosis and to Predict Affective Episodes in Bipolar Disorder","MoodCatcher","Inclusion Criteria:\n\nFor all participants:\n\n* Participants must be capable of giving informed consent.\n* Participants must be able to understand and follow the instructions in the project.\n* Access to a smartphone and ability to use a smartphone and actimeter.\n\nFor patients with bipolar disorder\n\n* Confirmed diagnosis of bipolar disorder (type 1 or type 2) according to ICD-10 after completion of an assessment at a psychiatric clinic in the Stockholm Region.\n* Patients must be euthymic (stable and free from affective episodes) at the time of inclusion.\n* Consent for the research team to access relevant clinical data from patient records.\n\nFor patients with recurrent depression\n\n* Confirmed diagnosis of recurrent depression according to ICD-10 after completion of an assessment at a psychiatric clinic in Region Stockholm.\n* Patients must have been referred for diagnostic assessment with the question of bipolar disorder.\n* Patients must be euthymic (stable and free from affective episodes) at the time of inclusion.\n\nExclusion Criteria:\n\nCommon to all participants:\n\n* Active substance abuse or dependence (alcohol or other substances).\n* Neurological disease or cognitive impairment that may affect study results or compliance with study procedures.\n* Inability to use a smartphone and smartwatch as required by the study.\n* Inability to provide valid informed consent.\n* Inability to understand and follow the study instructions (good knowledge of Swedish is required).\n\nFor adults without psychiatric illness:\n\n* Current or previous psychiatric diagnosis.\n\nFor patients with bipolar disorder and patients with recurrent depression:\n\n* Patients who are in an active affective episode (mania, hypomania or depression) at the time of recruitment.",{"count":421,"type":23},600,"12 Weeks","This trial has two studies. In study 1, the investigators will explore the relationships between three psychobiological factors (sleep patterns, motor activity, and decision-making ability). The investigators aim to investigate how these factors interact in BD patients. This understanding will facilitate the distinction of BD patients from patients with recurrent depressive disorder (MDD) and healthy controls.\n\nIn study 2, the investigators will continue following patients with bipolar disorder and use the interplay between the three psychobiological factors to develop early markers of full-blown affective episodes.",[172,28,425],"Bipolar Disorder (BD)",[427,91,428,429,430,431,432],"Mood disorders","Affective disorder assesment","Major depressive disorder","Cognition","Sleep","Activity","2026-02-17",{"date":435,"type":35},"2026-02-23",{"date":437,"type":23},"2026-04",{"date":439,"type":23},"2030-12",{"name":441,"class":42},"Karolinska Institutet",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":195,"enrollmentInfo":450,"targetDuration":4,"studyType":54,"phases":452,"briefSummary":453,"conditions":454,"keywords":460,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":75},"100545041","phase-2-search-for-novel-transcranial-magnetic-stimulation-tms-targets-for-mental-illness-100545041","NCT06376734","Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness","Transdiagnostic Circuit Mapping of Prefrontal Targets in Accelerated Transcranial Magnetic Stimulation","Expedition","Inclusion Criteria:\n\n* Age 18-65\n* English proficiency sufficient for informed consent, questionnaires\u002Ftasks, and treatment\n* Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5)\n\n  * ≥20 on the Beck Depression Inventory for patients with MDD\n  * ≥16 on the Beck Anxiety Inventory for patients with GAD\n  * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD\n  * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia\n* Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis).\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n\nExclusion Criteria:\n\n* Active pregnancy as determined by a urine pregnancy test\n* Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder)\n* PTSD with active, clinically significant symptoms, as determined by clinician\n* Diagnosis of Schizoaffective Disorder, Bipolar Type\n* Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine\u002Fesketamine\u002FECT)\n* Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI\n* Any other TMS or MRI safety concerns identified by the clinician\n* Receiving or planning to receive other TMS treatments during course of participation\n* History of:\n\n  * Neurosurgical intervention for mental illness\n  * Moderate to severe autism spectrum disorder\n  * Intellectual disability\n  * Severe cognitive impairment\n  * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis)\n  * Untreated or insufficiently treated endocrine disorder\n  * Eating disorders\n  * Treatment with investigational drug or intervention during the study period\n* Current evidence of:\n\n  * Mania or hypomania\n  * Active suicidal ideation or a suicide attempt within the past year\n  * Contraindications to either TMS or MRI (e.g., metallic implants, etc.).\n  * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n  * Significantly increased seizure risk as determined by a clinician\n* For participants with schizophrenia:\n\n  * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team\n  * Hospitalization with psychosis in the past 6 months\n* Positive urine drug screen for illicit substances\n* Existing tinnitus (ringing in the ears)\n* Any other condition deemed by the PI to interfere with the study or increase risk to the participant",{"count":451,"type":23},180,[158],"Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.",[172,392,455,456,28,457,458,459],"Schizophrenia","Generalized Anxiety Disorder","Psychiatric Disorder","Mental Disorder","Depression, Anxiety",[461,462,463,384,464,465,399,466,467,468,469,470,471,472,402,473],"depression","anxiety","schizophrenia","obsessive-compulsive disorder","transcranial magnetic stimulation","accelerated TMS","accelerated intermittent theta burst stimulation","brain stimulation","neuromodulation","transdiagnostic","neuronavigation","functional connectivity","theta burst stimulation","2026-02-13",{"date":433,"type":35},{"date":477,"type":35},"2025-01-30",{"date":479,"type":23},"2030-06-01",{"name":481,"class":42},"Brigham and Women's Hospital",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":195,"enrollmentInfo":490,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":104},"100622888","evaluate-the-effects-of-long-term-use-of-psychotropic-medications-on-eye-movement-patterns-with-the-gaize-device-100622888","NCT07389473","Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device","An Observational Study to Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device","Rx Meds Gaize","Inclusion Criteria:\n\n* Adults aged between 18 and 65, having given written informed consent to participate in the research trial.\n* Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.\n* Normal or corrected to normal vision using either glasses or contact lenses, or surgery.\n\nExclusion Criteria:\n\n* Enrolled in, or participated in another clinical trial within 30 days before the study\n* Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days.\n* Had your eyes dilated by a medical doctor in the previous 24 hours.\n* Photosensitive epilepsy\n* Diagnosed with clinical blindness\n* Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded.\n* Current or past head inject\u002F traumatic brain injury (TBI)\n* Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications.\n* History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well.\n* Potential participants who are unable to provide consent for the study.",{"count":156,"type":23},"The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.",[493,494,28,495,496],"ADHD","Depression Disorders","Anxiety Disorder Generalized","Bipolar Disorder (BPD)","2026-02-04",{"date":499,"type":35},"2026-02-05",{"date":501,"type":35},"2024-04-17",{"date":503,"type":23},"2028-08",{"name":505,"class":506},"Gaize","INDUSTRY",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":19,"minAge":322,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":54,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":75},"100581750","accelerated-vs-conventional-theta-burst-stimulation-for-late-life-depression-100581750","NCT06854367","Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression","ACT-LLD","Inclusion Criteria:\n\n1. are voluntary and competent to consent to treatment\n2. are an outpatient\n3. are ≥ 60 years old\n4. have a Mini International Neuropsychiatric Interview (MINI 7.0) confirmed diagnosis of MDD, with a current MDE\n5. have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of ≥ 3 in the current episode or have failed to tolerate two separate trials of an antidepressant\n6. have a score ≥ 10 on the Patient Health Questionnaire (PHQ-9)\n7. have had no increase or initiation of any antidepressant or antipsychotic medication in the 4 weeks prior to screening\n8. are able to adhere to the treatment schedule\n9. pass the TMS adult safety screening (TASS) questionnaire\n\nExclusion Criteria:\n\n1. have a Mini International Neuropsychiatric Interview (MINI 7.0) confirmed diagnosis of substance dependence or abuse within the last 3 months\n2. have a concomitant major unstable medical illness as determined by one of the study physicians\n3. have active suicidal intent\n4. have presumed or probable dementia or clinical evidence of dementia as assessed by Short Blessed Test score ≥ 10\n5. have a lifetime MINI diagnosis of bipolar I or II disorder, or primary psychotic disorder\n6. have current psychotic symptoms\n7. have a diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD\n8. have a diagnosis of any personality disorder as assessed by a study investigator to be primary and causing greater impairment than MDD\n9. did not respond to a course of ECT in the current depressive episode\n10. have received rTMS in the current episode; patients who have had rTMS in a previous episode would be eligible\n11. have a history of a primary seizure disorder or a seizure associated with an intracranial lesion\n12. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed\n13. have an implanted electronic device that is currently in function such as a defibrillator\n14. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview)\n15. have clinically significant laboratory abnormality, in the opinion of a study investigator\n16. currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant\n17. if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study",{"count":515,"type":23},280,[56],"The purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where participants receive a single TBS treatment daily) in late life depression. In addition, the study also aims to determine if specific patterns of stimulation are more or less effective. To do this, all participants will receive active treatments, but some of the participants in this study will receive accelerated TBS and some will receive once daily TBS.",[519,298,162,28],"Late Life Depression (LLD)",[521,522,523,524],"Brain stimulation","rTMS","Theta burst stimulation","Accelerated theta burst stimulation","2026-01-27",{"date":527,"type":35},"2026-01-28",{"date":529,"type":35},"2025-03-27",{"date":531,"type":23},"2029-12",{"name":533,"class":42},"Centre for Addiction and Mental Health",{"id":535,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":536,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":538,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":543,"leadSponsor":545,"locationsCount":43},"100547441",{"count":537,"type":23},900,[28,29,30],"2026-01-20",{"date":541,"type":35},"2026-01-22",{"date":37,"type":35},{"date":544,"type":23},"2026-03-31",{"name":41,"class":42},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":154,"enrollmentInfo":554,"targetDuration":4,"studyType":54,"phases":556,"briefSummary":557,"conditions":558,"keywords":561,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":104},"100620814","imagery-rescripting-in-primary-care-100620814","NCT07362511","Imagery Rescripting in Primary Care","Imagery Rescripting Within Primary Care to Manage Depression: A Single-Case Experimental Design","IMPACT MADE","Inclusion Criteria:\n\n* Main complaint of depressive feelings, as indicated by both the mental health assistant and the patient.\n* HADS score for the depression subscale ≥ 11.\n* Ability to understand, read, write and speak Dutch or English.\n* Age between 18 and 70.\n* Willingness to participate in the study and treatment.\n\nExclusion Criteria:\n\n* Acute suicide risk (BDI-II-item9 score of 3).\n* If the mental health assistant suspects that the patient may have a primary diagnosis of bipolar disorder, psychosis, substance use disorder, low IQ, or if the patient suffers from serious neurological problems such as dementia, then the patient is not included. There will not be a formal assessment of a primary diagnosis.",{"count":555,"type":23},12,[56],"In the current study we aim to investigate the feasibility, acceptability, and effectiveness of ImRs offered by mental health assistants within primary care to reduce depressive symptoms. In a single-case experimental design (SCED) study, the following hypotheses will be tested:\n\n1. ImRs results in a reduction of depressive symptoms compared to baseline, and this reduction lasts up to six months.\n2. Patients with complaints of depressive symptoms find ImRs an acceptable form of intervention when offered by mental health assistants within a general practice setting.\n\nParticipants will wait for 2-4 weeks and then receive 5 sessions of ImRs over a period of 10 weeks. During these sessions, negative memories related to their depressed feelings are rescripted.",[559,560,28],"Major Depressive Diorder","Low Self-Esteem",[562,63,563],"Imagery Rescripting","Primary care","2026-01-14",{"date":566,"type":35},"2026-01-23",{"date":568,"type":35},"2025-12-01",{"date":570,"type":23},"2027-01-31",{"name":572,"class":42},"University of Amsterdam",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":19,"minAge":195,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":54,"phases":582,"briefSummary":583,"conditions":584,"keywords":589,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":104},"100609222","integrated-care-for-older-adults-with-major-depression-and-physical-multimorbidity---the-i-connect-100609222","NCT07211750","Integrated Care for Older Adults With Major Depression and Physical Multimorbidity - The I-CONNECT","I-CONNECT","Inclusion Criteria:\n\n* Age 65 years or older\n* Clinical diagnosis of a mood disorder (depression or bipolar disorder)\n* Currently receiving care from a psychiatrist\n* At least two chronic physical health conditions\n* Living independently at home in the Leuven region\n* Ongoing care from both a general practitioner and a psychiatrist\n\nExclusion Criteria:\n\n* Severe cognitive impairment (e.g., advanced dementia) that prevents participation in assessments or shared decision-making\n* Inability to provide informed consent",{"count":581,"type":23},82,[56],"The goal of this clinical trial is to learn if I-CONNECT (Integrated Care for Older Adults with Major Depression and Physical Multimorbidity) can improve the health and well-being of older adults with depression or bipolar disorder and at least two chronic physical conditions, such as diabetes or high blood pressure. It will also study if the care model improves how people experience their care, lowers treatment burden, and how well the program is delivered.\n\nResearchers will compare two groups:\n\nI-CONNECT group: participants receive care coordination, a personalized care plan, medication review, shared decision-making support, and regular follow-up from a care coordinator working with their GP, psychiatrist, pharmacist, and specialists.\n\nUsual care group: participants continue with their normal healthcare from their GP and psychiatrist.\n\nParticipants will:\n\nReceive either I-CONNECT or usual care, depending on their group\n\nComplete questionnaires about their mood, quality of life, and care experience\n\nHave their healthcare use (emergency visits and hospitalizations) tracked during the study",[585,586,28,298,587,588],"Multimorbidity","Older Adults (65 Years and Older)","Bipolar","Integrated Care",[590,591,592,593,594,585,63,595,596,597],"Integrated care","Care coordination","Person-centered care","Shared decision-making","Self-management support","Bipolar disorder","Older adults","Quality of life","2025-12-11",{"date":600,"type":35},"2025-12-12",{"date":602,"type":35},"2025-10-01",{"date":604,"type":23},"2027-10-30",{"name":606,"class":42},"KU Leuven",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":18,"sex":19,"minAge":111,"maxAge":195,"enrollmentInfo":614,"targetDuration":4,"studyType":54,"phases":615,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":4},"100588553","evaluation-of-a-dietary-supplement-containing-melissa-officinalis-formulated-in-phospholipids-on-mood-well-being-and-cortisol-modulation-100588553","NCT06942897","Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation","Pilot Study for the Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Healthy volunteers as assessed by medical history and physical examination\n* Willingness to comply with the study procedures\n\nExclusion Criteria:\n\n* Current use of medications or supplements that may affect mood or cortisol levels\n* Known allergy or sensitivity to Melissa officinalis or phospholipids\n* History of psychiatric disorders (e.g., major depression, anxiety disorders)\n* Significant comorbidities (e.g., cardiovascular, hepatic, renal diseases)\n* Pregnant or breastfeeding women\n* Participation in another clinical trial in the past 30 days",{"count":294,"type":23},[56],"This is a randomized, double-blind, placebo-controlled pilot study designed to evaluate the effect of an oral nutritional supplement containing Melissa officinalis formulated in phospholipids on mood and cortisol levels in healthy adults. Participants will be randomly assigned to receive either the active supplement or a placebo daily for 3 weeks. The primary outcome measures include changes in mood well-being, perceived stress, and salivary cortisol levels. The study aims to assess both efficacy and safety of the supplement in modulating stress response and emotional balance.",[299,28,618],"Emotional Well-being","2025-11-23",{"date":621,"type":35},"2025-11-25",{"date":623,"type":23},"2026-06-15",{"date":625,"type":23},"2026-09-15",{"name":627,"class":42},"Azienda di Servizi alla Persona di Pavia",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":18,"sex":19,"minAge":111,"maxAge":195,"enrollmentInfo":635,"targetDuration":4,"studyType":54,"phases":637,"briefSummary":638,"conditions":639,"keywords":641,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":104},"100536354","cold-and-heat-investigation-to-lower-levels-of-depression-100536354","NCT06263738","Cold and Heat Investigation to Lower Levels of Depression","CHILL'D","Inclusion Criteria:\n\n* Individuals who currently meet study criteria for depression or individuals who do not currently meet criteria for depression\n* English or Spanish speaking (able to provide informed consent and complete questionnaires in one of these languages)\n* Able and willing to adhere to trial requirements, including attending all trial visits, preparatory and follow-up sessions, and completing all trial evaluations.\n\nExclusion Criteria:\n\n* Previous adverse reaction to hypothermia, hyperthermia and\u002For infrared exposure\n* Use of any medication that may impact thermoregulatory capacity.\n* Pregnancy, active lactation, or intention to become pregnant during the study period.\n* Endorses current active suicidal ideation with a plan or made a suicide attempt in the prior 6 months.",{"count":636,"type":23},162,[56],"This study will recruit 112 medically healthy adults (aged 18-65) currently experiencing depressive symptoms to be randomized to receive either a single Whole Body Hyperthermia (heat therapy) treatment or a Whole Body Hyperthermia treatment followed by a cold water plunge. Participants will complete a baseline assessment of their depressive symptoms as well as 1-week and 2-week post-treatment followup assessments.",[63,28,640],"Healthy (Controls)",[63,28,642,643,644,645,646],"Mental Health","Integrative Health","Hyperthermia","Sauna","Cold Plunge","2025-11-11",{"date":649,"type":35},"2025-11-13",{"date":651,"type":35},"2024-05-14",{"date":653,"type":23},"2027-04-01",{"name":655,"class":42},"Barry Sandler",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":18,"sex":19,"minAge":111,"maxAge":664,"enrollmentInfo":665,"targetDuration":4,"studyType":54,"phases":666,"briefSummary":667,"conditions":668,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":104},"100607434","youth-suicide-risk-factors-reduction-of-suicide-risk-factor-in-youth-people-100607434","NCT07188506","Youth Suicide Risk Factors, Reduction of Suicide Risk Factor in Youth People","Youth Suicide Risk Factors: Clinical, Neuroimaging, Genetic, and Microbiome Insights, and Predictors of Response to Deep Transcranial Magnetic Stimulation (dTMS)","YOU-SURF","Inclusion Criteria:\n\n* Diagnosis of mood disorder (major depressive episode, major depressive disorder, or bipolar disorder) according to DSM-5;\n* Age between 18 and 25 years;\n* Eligibility for magnetic resonance imaging;\n* Proficiency in the Italian language.\n\nExclusion Criteria:\n\n* Comorbidity with severe neurological or medical conditions;\n* Diagnosis of cognitive impairment;\n* Inability to provide informed consent.\n\nFor the control group:\n\nInclusion Criteria:\n\nthe same as the experimental group.\n\nExclusion Criteria:\n\n* subjects with DSM-5 disorders\n* subjects with a family history of psychiatric disorders will be excluded.","25 Years",{"count":451,"type":23},[56],"The YOU-SURF project is at the forefront of youth suicide prevention, with the goal of integrating multimodal clinical and neurobiological data to comprehensively identify risk factors and the most effective intervention strategies. Suicide is one of the leading causes of death among young people, with particularly alarming incidence rates during adolescence and early adulthood. Suicidal risk is a complex phenomenon, determined by a multiplicity of clinical, environmental, and biological factors. Emerging evidence suggests that information derived from neuroimaging, genetics, and the microbiome may also play a significant role. However, studies conducted to date have not yet adopted a truly multimodal approach that jointly integrates these dimensions in the identification of risk factors for suicide in youth. The YOU-SURF project aims to fill this critical gap.\n\nYOU-SURF will also pioneer the use of deep transcranial magnetic stimulation (dTMS), an innovative neuromodulation technique, whose effectiveness in reducing suicidal risk in young people will be assessed within a longitudinal design. Although some preliminary evidence suggests a potential benefit of neuromodulation treatments in this population, the specific effects of dTMS on suicidal risk in youth remain largely unexplored. Furthermore, there is a significant lack of knowledge regarding predictors of response to dTMS in young individuals at risk for self-harming behaviors.\n\nThe specific objectives of the project are as follows:\n\n1. To identify youth suicide risk factors through the integration of clinical, environmental, neuroimaging, genetic, and microbiome data;\n2. To longitudinally evaluate the effectiveness of dTMS in the treatment of young people at risk of suicide;\n3. To develop a predictive model based on machine learning techniques, grounded in multimodal data, to estimate the individual response to dTMS in this population.\n\nThe results of the project will provide a solid scientific basis for the development of personalized prevention and treatment interventions, improving clinical effectiveness and resource allocation in youth mental health services.",[28,669,670,671],"Suicide, Attempted","Suicidal Ideation","Suicide Prevention","2025-09-23",{"date":674,"type":35},"2025-09-29",{"date":676,"type":23},"2025-10-31",{"date":678,"type":23},"2028-10-31",{"name":680,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":682,"slug":683,"hasResults":12,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":687,"eligibilityCriteria":688,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":350,"enrollmentInfo":689,"targetDuration":4,"studyType":54,"phases":691,"briefSummary":692,"conditions":693,"keywords":694,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":701,"lastUpdatePostDateStruct":702,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":238},"100351703","mechanisms-of-rumination-change-in-adolescent-depression-100351703","NCT03859297","Mechanisms of Rumination Change in Adolescent Depression","Developing Rumination-focused Treatment to Reduce Risk for Depression Recurrence (RDR) in Adolescence","RuMeChange","Inclusion Criteria:\n\n* Previous diagnosis of Major Depressive Disorder (full or partial remission for at least two weeks) according to Diagnostic and Statistical Manual (DSM-V) criteria confirmed by the Kiddie Schedule for affective disorders (KSADSPL). Partial remission is defined as not meeting full DSM-V criteria for MDD.\n* RRS score above the age and sex specific mean, T \\> 50).\n* 14-17 years of age at enrollment (accounting for 2 year follow-up),\n* Postpubertal (Petersen Pubertal Developmental Scale)\n* Youth assent and parent consent\n* Intellectual Quotient (IQ) \\> 75, determined by Wechsler Abbreviated Scale of Intelligence (WASI)\n\nExclusion Criteria:\n\n* Endorsement of suicidality with plan or intent (assessed via KSADSPL and Children's Depression Rating Scale (CDRS-R) clinical interviews. Current or past (within previous three months) plan or intent is exclusionary.\n* Lifetime history of conduct disorder, autism, any psychotic disorder (or episode unexplained by other known medical causes), or bipolar disorder. Eating disorder or alcohol\u002Fsubstance abuse within the previous 6 months. (Lifetime history of an anxiety disorder, disruptive mood dysregulation disorder or oppositional defiant disorder, Attention Deficit Hyperactivity Disorder (ADHD) will not be exclusionary).\n* Current treatment with RF-CBT, Cognitive Behavioral Therapy (CBT), or variants thereof, or in the last 2 years. Likewise, detail oriented therapy beyond supportive therapy (e.g., homework, cognitive restructuring), in same time window (ability to recall elements of structured therapies with CBT focus).\n* Metal braces or retainers, tattoos with metal, or clothing with metal fibers.\n* Claustrophobia\n* Current pregnancy - Parents will be asked this information at the phone screen. At the clinic eligibility visit, female participants will be asked about sexual activity in a private room separate from their parents using the pregnancy script\u002Fscreen that the investigators have created. This script details that if a female is ineligible due to pregnancy or inadequate birth control, this information will not be disclosed to her parent(s). Participants who are sexually active will be asked about birth control method. Abstinence will be considered an approved form of contraception.\n* Psychotropic medication outside of antidepressants such as mood stabilizers and antipsychotics will be exclusionary. Participants may have a history of current, stable antidepressant medication use, with no changes in dose for the past four weeks, no change in specific medication for six weeks.",{"count":690,"type":23},183,[56],"This study will evaluate whether a newer treatment, rumination-focused cognitive behavioral treatment, which includes mindfulness and can be used to reduce ruminative habits, change ways in which key brain regions interact with each other (e.g.., often called connectivity), and whether these changes in habits and brain connectivity can reduce the risk for recurrence of depression in the next two years.",[172,28],[695,461,696,697,698,699,700],"rumination","brain imaging","cognitive behavioral therapy","rumination focused cognitive behavioral therapy","default mode network","rumination induction","2025-08-06",{"date":703,"type":35},"2025-08-11",{"date":705,"type":35},"2019-05-01",{"date":707,"type":23},"2029-03-02",{"name":709,"class":42},"Ohio State University",{"id":711,"slug":712,"hasResults":12,"nctId":713,"briefTitle":714,"officialTitle":715,"acronym":4,"eligibilityCriteria":716,"healthyVolunteers":12,"sex":19,"minAge":111,"maxAge":195,"enrollmentInfo":717,"targetDuration":4,"studyType":54,"phases":719,"briefSummary":720,"conditions":721,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":722,"lastUpdatePostDateStruct":723,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":729,"locationsCount":104},"100553049","suicide-specific-rumination-in-veterans-100553049","NCT06481033","Suicide Specific Rumination in Veterans","Reducing Suicide-Specific Rumination in Veterans Using Real-time Functional Magnetic Resonance Imaging Neurofeedback","Inclusion Criteria:\n\n* U.S. military veteran between 18-65 years old\n* negative pregnancy test on MRI scan days\n* score greater than or equal to 10 on the Suicide Rumination Scale\n* clinically stabilized on psychotropic medications\n* engaged in mental health care treatment\n* able to provide written, informed consent\n\nExclusion Criteria:\n\n* no major medical or neurological disorders that could interfere with treatment\n* moderate or severe traumatic brain injury\n* current imminent suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the assessor\n* any current psychotic disorder\n* MRI contraindications\n* any substance use disorder for substances other than cannabis or alcohol (mild alcohol or cannabis use disorder does not exclude participants but moderate or severe alcohol or cannabis substance use disorder is disqualifying)\n* pregnant or trying to become pregnant",{"count":718,"type":23},15,[56],"Few treatments target core features of suicidal thoughts and behaviors in Veterans. Real-time functional magnetic resonance imaging neurofeedback can provide information regarding brain activation associated with suicide-specific rumination, defined as a \"repetitive mental fixation on one's suicidal thoughts and intentions.\" The goal of this feasibility study is for Veterans to learn strategies for modulating activity within brain regions that have been demonstrated to contribute to the maintenance of rumination, as they receive neurofeedback feedback signals from the brain.",[63,161,28],"2025-07-30",{"date":724,"type":35},"2025-07-31",{"date":726,"type":35},"2024-08-01",{"date":728,"type":23},"2026-12-31",{"name":730,"class":731},"VA Office of Research and Development","FED"]